Impax Asset Management Group plc Sells 26,272 Shares of Becton, Dickinson and Company (NYSE:BDX)

Impax Asset Management Group plc trimmed its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 936,258 shares of the medical instruments supplier’s stock after selling 26,272 shares during the period. Impax Asset Management Group plc owned approximately 0.32% of Becton, Dickinson and Company worth $225,113,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of BDX. Financial Counselors Inc. boosted its stake in Becton, Dickinson and Company by 12.6% in the first quarter. Financial Counselors Inc. now owns 1,515 shares of the medical instruments supplier’s stock worth $375,000 after buying an additional 169 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Becton, Dickinson and Company in the first quarter worth approximately $252,000. TFB Advisors LLC boosted its stake in Becton, Dickinson and Company by 17.5% in the first quarter. TFB Advisors LLC now owns 1,410 shares of the medical instruments supplier’s stock worth $330,000 after buying an additional 210 shares in the last quarter. 9258 Wealth Management LLC purchased a new stake in Becton, Dickinson and Company in the first quarter worth approximately $203,000. Finally, DAVENPORT & Co LLC boosted its stake in Becton, Dickinson and Company by 2,495.2% in the first quarter. DAVENPORT & Co LLC now owns 225,680 shares of the medical instruments supplier’s stock worth $55,790,000 after buying an additional 216,984 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $234.33 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The company has a market cap of $67.73 billion, a PE ratio of 48.22, a P/E/G ratio of 1.75 and a beta of 0.43. The business has a 50 day moving average of $237.52 and a 200 day moving average of $235.10. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $259.92.

Wall Street Analyst Weigh In

BDX has been the subject of several research reports. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.